MARK FLOOD: Open Payments
NPI 1376729046 · HACKENSACK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 74 payments from 14 companies in 2025. Trend: 2023 $1,810 · 2024 $1,274 · 2025 $976
Food & beverage: $976
| Company | Payments | Amount |
|---|---|---|
| AbbVie Inc. | 26 | $181 |
| Teva Pharmaceuticals USA, Inc. | 11 | $181 |
| Neurocrine BioSciences, Inc. | 9 | $139 |
| Vanda Pharmaceuticals Inc. | 8 | $133 |
| Alkermes, Inc. | 4 | $78 |
| Neos Therapeutics, LP | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Tris Pharma Inc | 2 | $37 |
| Lundbeck LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $32 |
Products named: VRAYLAR, AUSTEDO XR, INGREZZA, FANAPT, ARISTADA, CAPLYTA, Dyanavel XR, HETLIOZ.
Industry payments across NJ — which companies pay providers there.
